Whitehawk Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
Rhea-AI Summary
Whitehawk Therapeutics (Nasdaq: WHWK), a company focused on developing advanced ADC cancer treatments, has announced its participation in the upcoming BTIG Virtual Biotechnology Conference. The conference is scheduled for July 29-30, 2025, where the company's management will present their developments in oncology therapeutics and ADC technology.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, WHWK gained 1.08%, reflecting a mild positive market reaction. This price movement added approximately $941K to the company's valuation, bringing the market cap to $88M at that time.
Data tracked by StockTitan Argus on the day of publication.
About Whitehawk Therapeutics
Whitehawk Therapeutics is an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.
Contact
IR@whitehawktx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-to-participate-in-the-btig-virtual-biotechnology-conference-302509852.html
SOURCE Whitehawk Therapeutics, Inc.
FAQ
When is Whitehawk Therapeutics (WHWK) presenting at the BTIG Virtual Biotechnology Conference?
What is Whitehawk Therapeutics' (WHWK) main business focus?
How can investors access Whitehawk Therapeutics' (WHWK) BTIG conference presentation?
Where is Whitehawk Therapeutics (WHWK) headquartered?
